
Consulting, Technology and Services for #LifeSciences companies. Clinical, Regulatory, Quality, PV, Medical Affairs domains.
Verona, Italy
Joined July 2012
- Tweets6.2K
- Following4.1K
- Followers1.6K
- Likes296
Arithmos retweeted
6️⃣ 2️⃣ ° 𝗦𝗜𝗠𝗣𝗢𝗦𝗜𝗢 𝗔𝗙𝗜 - 𝗚𝗟𝗜 𝗘𝗦𝗣𝗢𝗦𝗜𝗧𝗢𝗥𝗜
@ARITHMOS_LS
🔎 Scopri tutti i dettagli al link seguente:
simposio.afiscientifica.it/e…
#simposioafi2023
Arithmos retweeted
Are you trying to decide if you can do remote monitoring of your clinical trials? We have some guidance that may help.
agathahealth.com/the-future-…
#clinicaltrials #clinops
Arithmos retweeted
April 24th at 10am ET, we'll be joining partner @ARITHMOS_LS for a webinar on remote monitoring. Join us to learn to design your own tailored and compliant remote monitoring system. arithmostech.com/webinar-eff…
#remotemonitoring #clinops
Arithmos retweeted
We need safe, effective & high-quality medicines and vaccines to fight #COVID19. See how EMA will accelerate its regulatory procedures so that marketing authorisations can be granted ASAP:
👉ema.europa.eu/en/news/covid-…
#UnitedAgainstCoronavirus #GlobalResponse #StrongerTogether
Arithmos retweeted
We had a lot of great questions from the audience of our webinar with @ARITHMOS_LS - so we worked with them to create a Q&A. Here it is. arithmostech.com/questions-w…
Arithmos retweeted
🆕EMA establishes task force to take quick and coordinated regulatory actions in the 🇪🇺 related to #COVID19 medicines 💊
Check out its mandate:
👉ema.europa.eu/en/news/ema-es…
Arithmos retweeted
Researchers have developed a portable #AI device that can listen for coughs and sneezes and count the number of people present in public places to make predictions about levels of flu-like illnesses:
medgadget.com/2020/03/ai-dev…
Arithmos retweeted
All researchers are encouraged to register #pharmacoepidemiological studies related to #COVID19 medicines including #vaccines in the EU PAS Register: encepp.eu/encepp/studiesData…
Read more:
👉ema.europa.eu/en/human-regul…
Arithmos retweeted
Telemedicine benefits enormously during the Covid-19 pandemic. But is it here to stay? Will we stick to it or will we remember it as a “worse alternative”? Read a full article. #Telemedicine #COVID19 #SARSCoV2 #coronavirus #digitalhealth ictandhealth.com/news/teleme…
Arithmos retweeted
EMA’s human medicines committee (#CHMP) recommends 2 #medicines for approval at its February 2020 meeting: ema.europa.eu/en/news/meetin…
Arithmos retweeted
Machine learning and clinical insights: building the best model. #smartHIT bit.ly/2u8vpta
Arithmos retweeted
RWE: Cost and Time Savings Entice Sponsors as Pitfalls Linger | #Regulatory Focus ift.tt/2OVUVch
Arithmos retweeted
A majority believe healthcare is ahead of other industries in AI adoption, but 37% say healthcare’s pace of AI implementation is too slow. bit.ly/2UPi0Bm
Arithmos retweeted
According to the study, the AI alone showed 88.8% sensitivity in breast cancer detection, whereas radiologists alone showed 75.3%. When radiologists were aided by #AI, the accuracy increased by 9.5% to 84.8%. #smartHIT bit.ly/2Sor3HU
Arithmos retweeted
Discover how automation, cognitive technologies, and analytics are transforming #pharmacovigilance in our new report. #drugsafety #pharma deloi.tt/2UCtCaJ
Arithmos retweeted
When we talk about #interoperability, we tend to do so within an outdated framework that prioritizes ‘medicine’ over ‘health.’ We shouldn’t get stuck there, writes Dr. Charles Alessi, HIMSS International chief clinical officer. bit.ly/2H8UF5l
Arithmos retweeted
The digital future of the healthcare industry healtheuropa.eu/the-digital-… #digitalhealth
Arithmos retweeted
What constitutes suitable evidence for clinical implementation (and surveillance after) for #AI in #healthcare?
Here's @d_spiegel's take:
hdsr.mitpress.mit.edu/pub/56… @pubpub @harvard_data
Arithmos retweeted
Data and technology to play key role in Europe’s Beating Cancer Plan, says EU chief bit.ly/2ufndHT
Arithmos retweeted
Our latest outlook reveals that global #healthcare spending is expected to rise at a CAGR of 5% in 2019-23. Explore the opportunities this will likely present in 2020. deloi.tt/2OlpCXZ















